Key genetic modifications such as capsid engineering (e.g., Ad5/Ad37 fiber swaps), incorporation of immunostimulatory genes like IL-15, or the addition of tumor-targeting promoters (e.g., Ki67, hTERT) enable selective targeting of tumor cells and enhance antitumor immune activity. This evidence concerns the gene MKI67 and neoplasm.